{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:56Z","timestamp":1788675476150,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,2]]},"DOI":"10.7759\/cureus.79927","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T20:03:01Z","timestamp":1740945781000},"source":"Crossref","is-referenced-by-count":1,"title":["Clozapine-Induced Acute Pericarditis and Cardiac Tamponade: Early Recognition Improves Clinical Outcomes"],"prefix":"10.7759","author":[{"given":"Muhammad Waqar","family":"Elahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2016.12.008","article-title":"Why not clozapine for the patient with schizophrenia at risk of suicide?","volume":"26","author":"Bastiampillai T","year":"2017","unstructured":"Bastiampillai T, Tonnu O, Tibrewal P, Dhillon R. Why not clozapine for the patient with schizophrenia at risk of suicide?. Asian J Psychiatr. 2017, 26:6-7. 10.1016\/j.ajp.2016.12.008","journal-title":"Asian J Psychiatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119862535","article-title":"Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review","volume":"33","author":"Pardis P","year":"2019","unstructured":"Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. J Psychopharmacol. 2019, 33:1187-98. 10.1177\/0269881119862535","journal-title":"J Psychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis D","year":"2018","unstructured":"De Berardis D, Rapini G, Olivieri L, et al.. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018, 9:237-56. 10.1177\/2042098618756261","journal-title":"Ther Adv Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01064682","article-title":"Clinical profile of clozapine: adverse reactions and agranulocytosis","volume":"63","author":"Lieberman JA","year":"1992","unstructured":"Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992, 63:51-70. 10.1007\/BF01064682","journal-title":"Psychiatr Q"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000179","article-title":"Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report","volume":"34","author":"De Berardis D","year":"2014","unstructured":"De Berardis D, Campanella D, Serroni N, et al.. Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report. J Clin Psychopharmacol. 2014, 34:649-51. 10.1097\/JCP.0000000000000179","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","article-title":"Clozapine-induced pericarditis: an overlooked adverse effect","volume":"8","author":"Paul I","year":"2014","unstructured":"Paul I, Basavaraju V, Narayanaswamy JC, Math SB. Clozapine-induced pericarditis: an overlooked adverse effect. Clin Schizophr Relat Psychoses. 2014, 8:133-4.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000096666","article-title":"Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature","volume":"108","author":"Rathore S","year":"2007","unstructured":"Rathore S, Masani ND, Callaghan PO. Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature. Cardiology. 2007, 108:183-5. 10.1159\/000096666","journal-title":"Cardiology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian JG","year":"1999","unstructured":"Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999, 354:1841-5. 10.1016\/s0140-6736(99)10385-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-014-9304-9","article-title":"Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-\u03ba\u03b2","volume":"15","author":"Abdel-Wahab BA","year":"2015","unstructured":"Abdel-Wahab BA, Metwally ME. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-\u03ba\u03b2. Cardiovasc Toxicol. 2015, 15:355-65. 10.1007\/s12012-014-9304-9","journal-title":"Cardiovasc Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung JG","year":"2022","unstructured":"Leung JG, de Leon J, Frye MA, et al.. The modernization of clozapine: a recapitulation of the past in the United States and the view forward. J Clin Psychopharmacol. 2022, 42:565-80. 10.1097\/JCP.0000000000001606","journal-title":"J Clin Psychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen J","year":"2016","unstructured":"Nielsen J, Young C, Ifteni P, et al.. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016, 30:149-61. 10.1007\/s40263-016-0311-1","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.03.006","article-title":"Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review","volume":"199","author":"Knoph KN","year":"2018","unstructured":"Knoph KN, Morgan RJ 3rd, Palmer BA, et al.. Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review. Schizophr Res. 2018, 199:17-30. 10.1016\/j.schres.2018.03.006","journal-title":"Schizophr Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.16l02083","article-title":"An unmet need: a clozapine-induced myocarditis screening protocol","volume":"19","author":"Goldsmith DR","year":"2017","unstructured":"Goldsmith DR, Cotes RO. An unmet need: a clozapine-induced myocarditis screening protocol. Prim Care Companion CNS Disord. 2017, 19:10.4088\/PCC.16l02083","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson KJ","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al.. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011, 45:458-65. 10.3109\/00048674.2011.572852","journal-title":"Aust N Z J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001358","article-title":"Clozapine-associated myocarditis: a protocol for monitoring upon clozapine initiation and recommendations for how to conduct a clozapine rechallenge","volume":"41","author":"Griffin JM","year":"2021","unstructured":"Griffin JM, Woznica E, Gilotra NA, Nucifora FC Jr. Clozapine-associated myocarditis: a protocol for monitoring upon clozapine initiation and recommendations for how to conduct a clozapine rechallenge. J Clin Psychopharmacol. 2021, 41:180-5. 10.1097\/JCP.0000000000001358","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2015.07.002","article-title":"Clozapine-induced myocarditis: prevention and considerations in rechallenge","volume":"56","author":"Cook SC","year":"2015","unstructured":"Cook SC, Ferguson BA, Cotes RO, et al.. Clozapine-induced myocarditis: prevention and considerations in rechallenge. Psychosomatics. 2015, 56:685-90. 10.1016\/j.psym.2015.07.002","journal-title":"Psychosomatics"},{"key":"ref17","article-title":"Clozapine-induced pericarditis: outweighing risks versus benefits","author":"De Berardis D","year":"2020","unstructured":"De Berardis D, Ventriglio A, Orsolini L. Clozapine-induced pericarditis: outweighing risks versus benefits. Jr Amr Col Car. 2020,","journal-title":"Jr Amr Col Car"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/345244-clozapine-induced-acute-pericarditis-and-cardiac-tamponade-early-recognition-improves-clinical-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T20:03:03Z","timestamp":1740945783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/345244-clozapine-induced-acute-pericarditis-and-cardiac-tamponade-early-recognition-improves-clinical-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.79927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,2]]}}}